Xavier Fulladosa Oliveras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8126460/publications.pdf

Version: 2024-02-01

58 papers

1,834 citations

331670 21 h-index 42 g-index

60 all docs

60 docs citations

60 times ranked

1901 citing authors

#	Article	IF	CITATIONS
1	The Role of Inflammasomes in Glomerulonephritis. International Journal of Molecular Sciences, 2022, 23, 4208.	4.1	14
2	Th1 Cytokines Signature in 2 Cases of IgA Nephropathy Flare after mRNA-Based SARS-CoV-2 Vaccine: Exploring the Pathophysiology. Nephron, 2022, 146, 564-572.	1.8	5
3	Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?. CKJ: Clinical Kidney Journal, 2021, 14, 884-890.	2.9	13
4	Extracapillary proliferation scoring correlates with renal outcome and contributes to stratification in adult patients with immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2021, 14, 284-290.	2.9	2
5	Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review. International Journal of Molecular Sciences, 2021, 22, 2326.	4.1	3
6	MO335URINARY CYTOKINES REFLECT THE ONGOING RENAL INFLAMMATION IN THE DIAGNOSTIC OF ACUTE TUBULOINTERSTITIAL NEPHRITIS: RESULTS OF A MULTIPLEX BEAD-BASED ASSAY ASSESSMENT. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
7	Urinary Cytokines Reflect Renal Inflammation in Acute Tubulointerstitial Nephritis: A Multiplex Bead-Based Assay Assessment. Journal of Clinical Medicine, 2021, 10, 2986.	2.4	3
8	A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti–Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients. Kidney International Reports, 2020, 5, 1764-1776.	0.8	26
9	PO441CONCOMITANT MEDICATIONS OR IMMUNE CHECHKPOINT INHIBITOR, WHO IS THE CAUSE OF ACUTE TUBULOINTERSTITIAL NEPHRITIS IN IMMUNOTHERAPY?. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
10	P0196ACUTE TUBULOINTERSTITIAL NEPHRITIS (ATIN) INDUCED BY CHECKPOINT INHIBITORS (ICI) VERSUS CLASSICAL ATIN. ARE THEY THE SAME DISEASE?. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
11	New Biomarkers in Acute Tubulointerstitial Nephritis: A Novel Approach to a Classic Condition. International Journal of Molecular Sciences, 2020, 21, 4690.	4.1	10
12	Risk factors for non-diabetic renal disease in diabetic patients. CKJ: Clinical Kidney Journal, 2020, 13, 380-388.	2.9	14
13	T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach. CKJ: Clinical Kidney Journal, 2019, 12, 503-511.	2.9	31
14	Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain. CKJ: Clinical Kidney Journal, 2019, 12, 829-835.	2.9	4
15	SaOO11BIOPSY-PROVEN DIABETIC NEPHROPATHY WORSENS RENAL PROGNOSIS IN DIABETIC PATIENT: RESULTS MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2019, 34,	0.7	0
16	FP235Th17 RESPONSE IN ANCA ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
17	205.â $€f$ TH17 LYMPHOCYTE RESPONSE IN A COHORT OF ANCA-ASSOCIATED VASCULITIS PATIENTS. Rheumatology, 2019, 58, .	1.9	O
18	Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International, 2019, 96, 995-1004.	5. 2	52

#	Article	IF	CITATIONS
19	028. $\hat{a} \in f$ ANCA-MPO ANTIBODIES OF IGA ISOTYPE IN ANCA-ASSOCIATED VASCULITIS: PREVALENCE AND CLINICAL ASSOCIATIONS. Rheumatology, 2019, 58, .	1.9	0
20	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrologia, 2019, 39, 497-505.	0.4	1
21	Exploring Frequencies of Circulating Specific Th17 Cells against Myeloperoxidase and Proteinase 3 in ANCA Associated Vasculitis. International Journal of Molecular Sciences, 2019, 20, 5820.	4.1	4
22	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 373-379.	0.5	21
23	A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney International, 2019, 95, 219-231.	5. 2	208
24	A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney International, 2018, 93, 450-459.	5.2	100
25	FP200CALPROTECTIN AS A RENAL PROGNOSIS BIOMARKER IN ANCA ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2018, 33, i97-i98.	0.7	0
26	SP416DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY HAVE WORSE RENAL PROGNOSIS. STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.7	0
27	Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS ONE, 2018, 13, e0205982.	2.5	15
28	SP425RENAL BIOPSY IN DIABETIC PATIENTS: PRELIMINARY RESULTS OF THE SPANISH MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i491-i491.	0.7	0
29	Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1. American Journal of Kidney Diseases, 2018, 72, 411-418.	1.9	42
30	Treatment of multiple myeloma with renal involvement: the nephrologist's view. CKJ: Clinical Kidney Journal, 2018, 11, 777-785.	2.9	11
31	Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain. CKJ: Clinical Kidney Journal, 2018, 11, 468-473.	2.9	17
32	Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. CKJ: Clinical Kidney Journal, 2017, 10, 632-638.	2.9	4
33	The value of repeat biopsy in lupus nephritis flares. Medicine (United States), 2017, 96, e7099.	1.0	41
34	Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis: TableÂ1 CKJ: Clinical Kidney Journal, 2016, 9, 547-551.	2.9	14
35	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Reviews, 2014, 16, 199-212.	1.0	36
36	Consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34 Suppl 2, 1-81.	0.4	8

#	Article	IF	CITATIONS
37	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34, 768-88.	0.4	1
38	Acute renal failure induced by acute interstitial nephritis secondary to cocaine. Nefrologia, 2013, 33, 609-11.	0.4	5
39	Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 3596-3602.	0.7	28
40	False Hyperglycemies in Diabetic Patients Using Icodextrin in Peritoneal Dialysis. Dialysis and Transplantation, 2008, 37, 323-327.	0.2	5
41	Fluvastatin in the Prevention of Renal Transplant Vasculopathy: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Transplantation, 2008, 86, 82-87.	1.0	24
42	Glomerular adaptation after kidney transplantation. Transplantation Reviews, 2007, 21, 119-127.	2.9	4
43	Evaluation of pre-implantation kidney biopsies: Comparison of Banff criteria to a morphometric approach. Kidney International, 2005, 67, 1595-1600.	5.2	86
44	Risk factors associated with the deterioration of renal function after kidney transplantation. Kidney International, 2005, 68, S113-S117.	5.2	18
45	Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. Nephrology Dialysis Transplantation, 2005, 20, 2511-2516.	0.7	29
46	Glomerular Enlargement Assessed by Paired Donor and Early Protocol Renal Allograft Biopsies. American Journal of Transplantation, 2004, 4, 650-654.	4.7	24
47	Splicing alterations in human renal allografts: detection of a new splice variant of protein kinase Par1/Emk1 whose expression is associated with an increase of inflammation in protocol biopsies of transplanted patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1689, 58-65.	3.8	8
48	Baseline Immunosuppression is Associated with Histological Findings in Early Protocol Biopsies. Transplantation, 2004, 78, 1064-1068.	1.0	50
49	Structural and functional correlations in stable renal allografts. American Journal of Kidney Diseases, 2003, 41, 1065-1073.	1.9	9
50	Estimation of Total Glomerular Number in Stable Renal Transplants. Journal of the American Society of Nephrology: JASN, 2003, 14, 2662-2668.	6.1	93
51	Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney International, 2002, 61, 727-733.	5.2	109
52	Serial Protocol Biopsies to Quantify the Progression of Chronic Transplant Nephropathy in Stable Renal Allografts. American Journal of Transplantation, 2001, 1, 82-88.	4.7	74
53	PROTOCOL RENAL ALLOGRAFT BIOPSIES AND THE DESIGN OF CLINICAL TRIALS AIMED TO PREVENT OR TREAT CHRONIC ALLOGRAFT NEPHROPATHY1. Transplantation, 2000, 69, 1849-1855.	1.0	98
54	RECIPIENT BODY SURFACE AREA AS A PREDICTOR OF POSTTRANSPLANT RENAL ALLOGRAFT EVOLUTION1. Transplantation, 1998, 65, 671-676.	1.0	66

#	Article	IF	CITATIONS
55	LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2. Transplantation, 1998, 66, 1727-1731.	1.0	100
56	Early protocol renal allograft biopsies and graft outcome. Kidney International, 1997, 51, 310-316.	5.2	223
57	STEROID WITHDRAWAL IN MYCOPHENOLATE MOFETIL-TREATED RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1997, 63, 1688-1690.	1.0	72
58	Avoiding immunogenic drugs is key to preserve renal function in patients receiving immune checkpoint inhibitors: Lessons learned from three illustrative cases. Journal of Onco-Nephrology, 0, , 239936932110485.	0.6	1